Epilepsy News and Research

Latest Epilepsy News and Research

Research on method to open blood-brain barrier for safe cancer drug delivery

One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.

28 Jul 2010

Epilepsy drugs analyzed for causing increased risk of suicide in patients

While the Food and Drug Administration requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Newer drugs with a higher risk of causing depression than other epilepsy drugs, such as levetiracetam, topiramate and vigabatrin, were found to increase the risk of self-harm or suicidal behavior among people with epilepsy.

27 Jul 2010

Fatal risk of software defects in implantable medical devices

Software vulnerabilities in life-sustaining medical devices such as pacemakers and infusion pumps pose a growing threat to public health, warns a new report published by the Software Freedom Law Center (SFLC).

22 Jul 2010

New campaign empowers, inspires women and families affected by epilepsy

A new campaign explores the roles and responsibilities women uniquely encounter when living, or caring for a loved one, with epilepsy. "Women Succeeding with Epilepsy" is a collaboration between Epilepsy Advocate and HealthyWomen to educate, empower and inspire women and families whose lives are affected by epilepsy.

22 Jul 2010

Major turning point in antiepileptic drug testing, development

New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

21 Jul 2010

Traumatic brain injuries during war increase risk of epilepsy even decades later

Soldiers who receive traumatic brain injuries during war may be at a higher risk of epilepsy even decades after the brain injury occurred. The new research is published in the July 20, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jul 2010

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

A group of researchers from Universidad Carlos III de Madrid has presented a new algorithm that uses a new method to analyse the information obtained from electroencephalograms to detect neurodegenerative diseases, such as epilepsy, using the bioelectric signals of the brain.

20 Jul 2010

Eisai's NDA for BANZEL Oral Suspension accepted for FDA review

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL).

19 Jul 2010

Johns Hopkins Hospital takes top spot in annual rankings of American hospitals for 20th year in a row

Once more — and for the 20th year in a row — The Johns Hopkins Hospital has taken the top spot in U.S. News & World Report's annual rankings of American hospitals, placing first in five medical specialties and in the top five in 10 others.

16 Jul 2010

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, inclusive, with ADHD. Supernus expects to enroll 50 subjects in the study at 5 sites across the United States.

14 Jul 2010

New research shows head size helps measure brain reserve, brain growth

New research shows that people with Alzheimer's disease who have large heads have better memory and thinking skills than those with the disease who have smaller heads, even when they have the same amount of brain cell death due to the disease. The research is published in the July 13, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

13 Jul 2010

Investment report on Catalyst Pharmaceutical Partners

MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

12 Jul 2010

Cross-disciplinary research experts develop Responsive Epilepsy Control System

The Brain Mind Welfare Team of National Cheng Kung University, Tainan, Taiwan, formed by cross-disciplinary research experts from information engineering, medical information and social science, has developed a Responsive Epilepsy Control System which proved to be successful in epileptic rats.

12 Jul 2010

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.

9 Jul 2010

Depression increases risk of developing dementia later in life

A new study shows that having depression may nearly double your risk of developing dementia later in life. The research will be published in the July 6, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.

6 Jul 2010

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

2 Jul 2010

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis.

1 Jul 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

New brain-to-computer chip technology revolutionizes neurological therapy

By stimulating certain areas of the brain, scientists can alleviate the effects of disorders such as depression or Parkinson's disease. That's the good news. But because controlling that stimulation currently lacks precision, over-stimulation is a serious concern - losing some of its therapeutic benefits for the patient over time.

29 Jun 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Research on method to open blood-brain barrier for safe cancer drug delivery

Epilepsy drugs analyzed for causing increased risk of suicide in patients

Fatal risk of software defects in implantable medical devices

New campaign empowers, inspires women and families affected by epilepsy

Major turning point in antiepileptic drug testing, development

Traumatic brain injuries during war increase risk of epilepsy even decades later

Researchers use bioelectric signals of brain to detect neurodegenerative diseases

Eisai's NDA for BANZEL Oral Suspension accepted for FDA review

Johns Hopkins Hospital takes top spot in annual rankings of American hospitals for 20th year in a row

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

New research shows head size helps measure brain reserve, brain growth

Investment report on Catalyst Pharmaceutical Partners

Cross-disciplinary research experts develop Responsive Epilepsy Control System

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

NeuroPace submits PMA to FDA for world's first responsive neurostimulation system

Depression increases risk of developing dementia later in life

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New brain-to-computer chip technology revolutionizes neurological therapy

Everything you need to know about epilepsy eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Epilepsy News and Research

Latest Epilepsy News and Research

Everything you need to know about epilepsy eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in